CAT-2003
/ Astria Therap
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
December 27, 2018
Arid1a loss drives non-alcoholic steatohepatitis in mice via epigenetic dysregulation of hepatic lipogenesis and fatty acid oxidation.
(PubMed, Hepatology)
- "Inhibition of lipogenesis using CAT-2003, a potent sterol regulatory element-binding protein inhibitor, mediated improvements in markers of fatty liver disease progression in this Arid1a/Pten double knockout model. ARID1A plays a role in the epigenetic regulation of hepatic lipid homeostasis, and its suppression contributes to fatty liver pathogenesis. Combined Arid1a and Pten deletion shows accelerated fatty liver disease progression and is a useful mouse model for studying new therapeutic strategies for NASH."
Journal • Fibrosis • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Immunology • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis • Oncology • Solid Tumor
May 19, 2015
Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia
(clinicaltrials.gov)
- P2; N=13; Completed; Sponsor: Catabasis Pharmaceuticals; Active, not recruiting -> Completed
Trial completion • Biosimilar • Dyslipidemia • Hemophilia
August 28, 2013
Catabasis to present phase 1 data from Oral SMART linker conjugate CAT-2003 at Upcoming Conference
(Catabasis Press Release)
- “...new clinical data on the inhibition of PCSK9* by its oral SMART Linker conjugate, CAT-2003, will be presented at the Physicians Academy for Continuing Education (PACE) conference in Amsterdam on Aug. 31...The presentation will include results from CAT-2003’s recently completed Phase 1 trial.”
Anticipated conference • Anticipated P1 data • Atherosclerosis • Dyslipidemia
1 to 3
Of
3
Go to page
1